ALLO — Allogene Therapeutics Inc

Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on NASDAQ. It is led by David D. Chang M.D., Ph.D., based in 210 East Grand Avenue, South San Francisco, CA, United States, 94080, with about 226 employees. Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Latest reported ALLO revenue for 2025-09-30 was $0. Net income was -$152.1M. ALLO currently screens at market cap $258.1M.

Use this ALLO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ALLO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ALLO SEC filings page. Lician reads the product cache first so this HTML stays unique to Allogene Therapeutics Inc even when a live quote feed is slow.